NEOS Investment Management LLC Has $72.07 Million Stock Position in AbbVie Inc. $ABBV

Key Points

• NEOS Investment Management increased its AbbVie position by 10.4% in the second quarter, holding 286,410 shares valued at approximately $72.07 million. Institutional investors and hedge funds collectively own 70.23% of ABBV.
• AbbVie exceeded quarterly expectations with adjusted EPS of $3.65 and revenue of $16.99 billion, while revenue rose 10.2% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $276.64.
• Shares opened at $255, near their 52-week high, but investors face risks including a high valuation, reliance on Skyrizi growth, Humira’s patent-related decline and an FDA setback for trenibotE. An executive also sold 32,710 shares worth about $8.18 million.

NEOS Investment Management LLC increased its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 10.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 286,410 shares of the company's stock after acquiring an additional 26,944 shares during the period. NEOS Investment Management LLC's holdings in AbbVie were worth $72,072,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. ACT Advisors LLC. lifted its position in shares of AbbVie by 2.5% in the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company's stock worth $425,000 after purchasing an additional 41 shares in the last quarter. Willner & Heller LLC increased its stake in AbbVie by 0.7% in the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company's stock valued at $1,472,000 after buying an additional 43 shares during the period. B.O.S.S. Retirement Advisors LLC increased its stake in AbbVie by 3.1% in the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company's stock valued at $359,000 after buying an additional 43 shares during the period. Fielder Capital Group LLC lifted its position in AbbVie by 1.7% in the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company's stock worth $637,000 after buying an additional 43 shares in the last quarter. Finally, Leslie Global Wealth LLC lifted its position in AbbVie by 1.5% in the 2nd quarter. Leslie Global Wealth LLC now owns 2,983 shares of the company's stock worth $751,000 after buying an additional 44 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Qulipta migraine expansion: AbbVie reported positive Phase 3 LUNA results for atogepant (Qulipta) in preventing menstrual migraine. The treatment met its primary and secondary endpoints, potentially opening a new indication and supporting intermittent use rather than continuous daily dosing. This could expand Qulipta’s commercial opportunity and reinforce AbbVie’s position in migraine care. AbbVie's migraine treatment meets late-stage study goal
• Positive Sentiment: Higher HSBC valuation: HSBC raised its price target for AbbVie to $315 from $300 while maintaining a Buy rating, signaling continued confidence in the company’s growth outlook and product pipeline. HSBC adjusts price target on AbbVie
• Positive Sentiment: Dividend maintained: AbbVie declared a quarterly cash dividend of $1.73 per share, payable Nov. 16 to shareholders of record Oct. 15. The unchanged payout supports the stock’s income appeal and reflects continued shareholder-return capacity. AbbVie declares quarterly dividend
• Neutral Sentiment: Pipeline and portfolio developments: Coverage highlighted the growth of Skyrizi and Rinvoq, the planned $10.9 billion Apogee Therapeutics acquisition, an ADARx collaboration and updated real-world data from an eye-implant study. These initiatives may diversify future growth, but their financial impact remains dependent on execution, approvals and clinical outcomes.
• Negative Sentiment: Regulatory setback: The FDA issued a Complete Response Letter for trenibotE, AbbVie’s fast-acting neurotoxin candidate. The action may delay the product’s launch and add uncertainty around the aesthetics pipeline. FDA issues Complete Response Letter for AbbVie’s trenibotE
• Negative Sentiment: Concentration and valuation concerns: Analysts continue to monitor AbbVie’s reliance on Skyrizi and the long-term effects of Humira’s patent-related decline. With the stock trading at a relatively elevated earnings multiple, execution risks and slower-than-expected diversification could limit further upside.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.06% of the company's stock.

AbbVie Stock Up 1.6%

Shares of ABBV opened at $255.00 on Friday. The company's fifty day moving average is $254.54 and its 200-day moving average is $230.76. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47. The firm has a market cap of $450.52 billion, a price-to-earnings ratio of 72.03, a price-to-earnings-growth ratio of 1.13 and a beta of 0.29.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie's quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts predict that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were given a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. AbbVie's payout ratio is currently 195.48%.

Analyst Upgrades and Downgrades

ABBV has been the topic of several research analyst reports. Bank of America restated a "buy" rating on shares of AbbVie in a report on Tuesday. Erste Group Bank upgraded AbbVie from a "hold" rating to a "buy" rating in a report on Wednesday, August 5th. Royal Bank Of Canada lifted their price objective on AbbVie from $260.00 to $280.00 and gave the company an "outperform" rating in a research report on Friday, July 10th. UBS Group boosted their target price on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a research note on Monday, July 13th. Finally, Canaccord Genuity Group upped their target price on AbbVie from $282.00 to $290.00 and gave the stock a "buy" rating in a research report on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $276.64.

AbbVie Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott's diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie's immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.